638 related articles for article (PubMed ID: 32251926)
1. Review of precision cancer medicine: Evolution of the treatment paradigm.
Tsimberidou AM; Fountzilas E; Nikanjam M; Kurzrock R
Cancer Treat Rev; 2020 Jun; 86():102019. PubMed ID: 32251926
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial design in the era of precision medicine.
Fountzilas E; Tsimberidou AM; Vo HH; Kurzrock R
Genome Med; 2022 Aug; 14(1):101. PubMed ID: 36045401
[TBL] [Abstract][Full Text] [Related]
3. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
5. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
6. Overview of precision oncology trials: challenges and opportunities.
Fountzilas E; Tsimberidou AM
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):797-804. PubMed ID: 30044653
[TBL] [Abstract][Full Text] [Related]
7. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
8. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
9. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
10. Innovative trial design in precision oncology.
Tsimberidou AM; Müller P; Ji Y
Semin Cancer Biol; 2022 Sep; 84():284-292. PubMed ID: 33022355
[TBL] [Abstract][Full Text] [Related]
11. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.
Said R; Tsimberidou AM
Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392
[TBL] [Abstract][Full Text] [Related]
12. Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
Mukherjee S
Cancer Biother Radiopharm; 2019 Oct; 34(8):487-497. PubMed ID: 31314580
[TBL] [Abstract][Full Text] [Related]
13. Complexity of Delivering Precision Medicine: Opportunities and Challenges.
Davis AA; McKee AE; Kibbe WA; Villaflor VM
Am Soc Clin Oncol Educ Book; 2018 May; 38():998-1007. PubMed ID: 30231318
[TBL] [Abstract][Full Text] [Related]
14. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
[TBL] [Abstract][Full Text] [Related]
15. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
Umelo IA; Costanza B; Castronovo V
Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
17. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
Masuda M; Nakagawa R; Kondo T
Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
[TBL] [Abstract][Full Text] [Related]
19. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
20. Molecular screening programs in different countries: what we learned and perspectives.
Borcoman E; Le Tourneau C; Kamal M
Curr Opin Oncol; 2019 Sep; 31(5):445-453. PubMed ID: 31261171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
